1. Home
  2. ATOS vs PFX Comparison

ATOS vs PFX Comparison

Compare ATOS & PFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATOS
  • PFX
  • Stock Information
  • Founded
  • ATOS 2009
  • PFX 2010
  • Country
  • ATOS United States
  • PFX United States
  • Employees
  • ATOS N/A
  • PFX N/A
  • Industry
  • ATOS Biotechnology: Pharmaceutical Preparations
  • PFX Finance: Consumer Services
  • Sector
  • ATOS Health Care
  • PFX Finance
  • Exchange
  • ATOS Nasdaq
  • PFX Nasdaq
  • Market Cap
  • ATOS 96.8M
  • PFX 98.8M
  • IPO Year
  • ATOS 2012
  • PFX N/A
  • Fundamental
  • Price
  • ATOS $0.65
  • PFX $52.35
  • Analyst Decision
  • ATOS Strong Buy
  • PFX
  • Analyst Count
  • ATOS 3
  • PFX 0
  • Target Price
  • ATOS $7.00
  • PFX N/A
  • AVG Volume (30 Days)
  • ATOS 520.3K
  • PFX 2.3K
  • Earning Date
  • ATOS 03-25-2025
  • PFX 05-09-2025
  • Dividend Yield
  • ATOS N/A
  • PFX 5.07%
  • EPS Growth
  • ATOS N/A
  • PFX N/A
  • EPS
  • ATOS N/A
  • PFX 8.16
  • Revenue
  • ATOS N/A
  • PFX $22,676,403.00
  • Revenue This Year
  • ATOS N/A
  • PFX $16.80
  • Revenue Next Year
  • ATOS N/A
  • PFX $0.74
  • P/E Ratio
  • ATOS N/A
  • PFX $6.61
  • Revenue Growth
  • ATOS N/A
  • PFX 7.21
  • 52 Week Low
  • ATOS $0.65
  • PFX $42.50
  • 52 Week High
  • ATOS $2.31
  • PFX $57.40
  • Technical
  • Relative Strength Index (RSI)
  • ATOS 31.82
  • PFX 44.89
  • Support Level
  • ATOS $0.66
  • PFX $52.35
  • Resistance Level
  • ATOS $0.71
  • PFX $54.77
  • Average True Range (ATR)
  • ATOS 0.04
  • PFX 0.27
  • MACD
  • ATOS -0.00
  • PFX -0.21
  • Stochastic Oscillator
  • ATOS 0.00
  • PFX 0.15

About ATOS Atossa Therapeutics Inc.

Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

About PFX PhenixFIN Corporation

PhenixFIN Corp is a non-diversified closed end management investment company operating in United States. Its investment objective is to generate current income and capital appreciation by lending directly to privately held middle market companies to expand their business, refinance and make acquisitions. It mainly invests in senior secured first lien term loans, senior secured second lien term loans, unitranche, senior secured first lien notes, subordinated notes and warrants and minority equity securities. It may also invest in securities of foreign companies. Portfolio of the company mainly consists of securities across all sectors. Revenue generated by the company comprises of interest income, dividend and other income earned through investments made.

Share on Social Networks: